Target intelligence / Profile preview

Chitinase-like protein (CLP)

Target
CLP
Molecular classification
Glycosyl hydrolase family 18, Lectin, Secreted glycoprotein
01

Overview

Chitinase-like proteins (CLPs) are a group of evolutionarily conserved glycoproteins belonging to the glycosyl hydrolase 18 (GH18) family (UniProt). While they share structural homology with active chitinases, CLPs lack the essential catalytic residues required to hydrolyze chitin, instead functioning as signaling molecules and lectins (PubMed: 22524424). The most extensively studied member, Chitinase-3-like protein 1 (CHI3L1 or YKL-40), is secreted by macrophages, chondrocytes, and cancer cells in response to cytokines like IL-6 and TNF-alpha (NIH: PMC4141375). CLPs play pivotal roles in regulating the innate immune response, promoting cell proliferation, and facilitating tissue remodeling and angiogenesis (PubMed: 30214036). In clinical contexts, elevated levels of CLPs are strongly associated with chronic inflammatory conditions, such as asthma and rheumatoid arthritis, as well as poor prognosis in various malignancies (PubMed: 29104119). Therapeutic development focuses on neutralizing these proteins using monoclonal antibodies or small molecules to disrupt their interaction with receptors like IL-13Rα2 and TMEM219, which drive pathological fibro-inflammatory and oncogenic pathways (PubMed: 32814544).

Other names
Chitinase-3-like protein 1CHI3L1YKL-40Chitinase-3-like protein 2CHI3L2YKL-39Breast regression protein 39Brp-39Stabilin-1-interacting chitinase-like proteinSI-CLP
02

Mechanism of action

Neutralization of secreted protein to prevent binding to receptors such as IL-13Rα2, TMEM219, or CD44, thereby inhibiting downstream pro-inflammatory and pro-survival signaling pathways.

03

Biological functions

Immune responseInflammationTissue remodelingCell proliferationApoptosis inhibitionAngiogenesisMacrophage polarizationExtracellular matrix organization
04

Disease associations

CancerAsthmaChronic obstructive pulmonary diseaseRheumatoid arthritisLiver fibrosisAlzheimer's diseaseCardiovascular diseaseDiabetesIdiopathic pulmonary fibrosis
05

Safety considerations

Potential impairment of host defense against chitin-containing pathogens (e.g., fungi, parasites)Off-target inhibition of enzymatically active chitinases like AMCaseSystemic effects due to broad expression in various tissues during wound healing
06

Interacting drugs

RG7625

4 more in the full profile.

07

Biomarkers

Serum YKL-40 levelsCerebrospinal fluid YKL-40Plasma CHI3L1Synovial fluid CHI3L1

Beyond the preview

Go deeper on Chitinase-like protein (CLP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chitinase-like protein (CLP).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call